ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)

FINANCIAL STATEMENTS AND AUDITORS' REPORT

SEPTEMBER 30, 2010
TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>TABLE</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>INDEPENDENT AUDITORS' REPORT</td>
<td>1</td>
</tr>
<tr>
<td>FINANCIAL STATEMENTS</td>
<td></td>
</tr>
<tr>
<td>Statement of Financial Position</td>
<td>2</td>
</tr>
<tr>
<td>Statement of Activities</td>
<td>3</td>
</tr>
<tr>
<td>Statement of Functional Expenses</td>
<td>4</td>
</tr>
<tr>
<td>Statement of Cash Flows</td>
<td>6</td>
</tr>
<tr>
<td>Notes to Financial Statements</td>
<td>7</td>
</tr>
</tbody>
</table>
INDEPENDENT AUDITORS' REPORT

To the Board of Directors of
Advancement of Research for Myopathies (ARM)
Reseda, California

We have audited the accompanying statements of financial position of Advancement of Research for Myopathies - ARM (the "Organization") (a California non-profit Organization) as of September 30, 2010, and the related statements of activities, functional expenses, and cash flows for the year then ended. These financial statements are the responsibility of the Organization's management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Advancement of Research for Myopathies - ARM as of September 30, 2010, and the results of its operations and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

March 4, 2011
ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)
Statement of Financial Position
September 30, 2010

ASSETS

Current Assets
Cash

Total current assets 133,492

Fixed assets
Office equipment 401
Less accumulated depreciation

Total fixed assets

Total assets $133,492

LIABILITIES AND NET ASSETS

Current liabilities $-

Contingencies-

Net assets - Unrestricted 133,492

Total liabilities and net assets $133,492

The accompanying notes are an integral part of these financial statements.
ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)
Statement of Activities
Year Ended September 30, 2010

REVENUES:
  Contributions and grants $ 490,019

  Total revenues 490,019

EXPENSES:
  Program services:
    Primary research 47,250
    Research development and patient services 162,181
  Total program services 209,431

  Support services:
    General and administrative 28,977
    Fundraising 170,619
  Total support services 199,596

  Total expenses 409,027

Increase in unrestricted net assets 80,992

Unrestricted net assets at beginning of year 52,500

Unrestricted net assets at end of year $ 133,492

The accompanying notes are an integral part of these financial statements.
ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)
Statement of Functional Expenses
For the Year ended September 30, 2010

<table>
<thead>
<tr>
<th>PROGRAM SERVICES</th>
<th>SUPPORT SERVICES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total Program Services</td>
</tr>
<tr>
<td>Grants and allocations</td>
<td>$ 182,894</td>
</tr>
<tr>
<td>Fund-raising activities</td>
<td>-</td>
</tr>
<tr>
<td>Other salaries and wages</td>
<td>9,000</td>
</tr>
<tr>
<td>Program awareness</td>
<td>16,631</td>
</tr>
<tr>
<td>Legal and professional fees</td>
<td>-</td>
</tr>
<tr>
<td>Payroll taxes</td>
<td>906</td>
</tr>
<tr>
<td>Travel</td>
<td>-</td>
</tr>
<tr>
<td>Rent</td>
<td>-</td>
</tr>
<tr>
<td>Credit card fees</td>
<td>-</td>
</tr>
<tr>
<td>Telephone</td>
<td>-</td>
</tr>
<tr>
<td>Office expenses</td>
<td>-</td>
</tr>
<tr>
<td>Printing and visual aids</td>
<td>-</td>
</tr>
<tr>
<td>Bank fees</td>
<td>-</td>
</tr>
<tr>
<td>Postage and shipping</td>
<td>-</td>
</tr>
<tr>
<td>Licenses and permits</td>
<td>-</td>
</tr>
</tbody>
</table>

The accompanying notes are an integral part of these financial statements.
ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)
Statement of Functional Expenses
For the Year ended September 30, 2010

<table>
<thead>
<tr>
<th>PROGRAM SERVICES</th>
<th>SUPPORT SERVICES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dues and subscriptions</strong></td>
<td><strong>-</strong></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>209,431</strong></td>
</tr>
</tbody>
</table>

The accompanying notes are an integral part of these financial statements.
ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)
Statement of Cash Flows
Year Ended September 30, 2010

CASH FLOWS FROM OPERATING ACTIVITIES:

Increase in unrestricted net assets $ 80,992
Adjustments to reconcile increase in unrestricted net assets to net cash provided by operating activities:
   Changes in assets and liabilities: 822
   Decrease in receivables
   Decrease in accrued expenses (4,315)

NET INCREASE IN CASH AND CASH EQUIVALENTS 77,499

CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR 55,993

CASH AND CASH EQUIVALENTS AT END OF YEAR $ 133,492

The accompanying notes are an integral part of these financial statements.
NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Activities

Advancement of Research for Myopathies (the “Organization”) is a non-profit corporation organized to provide funds for development of effective treatments for autosomal recessive inclusion body myopathy (IBM2). IBM2 is also known as quadriceps spring myopathy (QSM), distal myopathy with rimmed vacuoles (DMRV or nonka’s myopathy), or hereditary inclusion body myopathy (HIBM).

Basis of Accounting

The financial statements of Advancement of Research for Myopathies have been prepared on the accrual basis of accounting in accordance with generally accepted accounting principles.

Statement of Cash Flows

For the purposes of the statement of cash flows, the Organization considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.

Fixed Assets

Property and equipment are stated at cost. Depreciation on assets is provided for in amounts sufficient to relate the cost of depreciable assets to operations over their estimated service lives. The straight-line method of depreciation is followed for all assets.

Income Taxes

Advancement of Research for Myopathies is exempt from federal income taxes under Section 501 (c) (3) of the Internal Revenue Code and did not conduct unrelated business activities. Therefore, Advancement of Research for Myopathies has made no provision for federal income taxes in the accompanying financial statements.

Functional Allocation of Expenses

The costs of providing the various programs and other activities have been summarized on a functional basis in the statement of activities. Accordingly, certain costs have been allocated among the programs and supporting services benefited.
NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

Restriction of Funds

All funds in the various bank accounts are unrestricted funds.

NOTE 2 – BASIS FOR GRANTS PAYABLE

Grants awards may extend a period of 1-3 years and are paid on a quarterly basis. The Organization records the initial year’s liabilities and related expenses for the awarded grants after recommended for approval by the Organization’s independent scientific peer reviewers and approved by the Board of Directors. Funding of the remaining committed future amounts of grants is contingent upon satisfactory scientific and/or medical review and the availability of funds. For the year ended September 30, 2009, $330,341 in grants were paid to HIBM Research Group, Inc., which is a non-profit organization with the main purpose of engaging in medical research regarding Hereditary Inclusion Body Myopathies (HIBM).

NOTE 3 – FUNDRAISING ACTIVITIES

Advancement of Research for Myopathies (ARM) organizes special events to increase awareness and raise funds for biomedical research.

NOTE 4 – FIXED ASSETS

As of September 30, 2010, fixed assets consist of:

<table>
<thead>
<tr>
<th>Equipment Description</th>
<th>$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Office equipment</td>
<td>401</td>
</tr>
<tr>
<td>Less accumulated depreciation</td>
<td>401</td>
</tr>
</tbody>
</table>

$____
NOTE 5 - COMMITMENTS

The Organization entered into a one-year joint lease agreement with one other tenant for office space rental in June 2009. The lease was extended for another year to June 30, 2011.

<table>
<thead>
<tr>
<th>YEAR</th>
<th>RENT EXPENSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>$ 3,375</td>
</tr>
<tr>
<td>2012</td>
<td>-</td>
</tr>
<tr>
<td>2013</td>
<td>-</td>
</tr>
<tr>
<td>2014</td>
<td>-</td>
</tr>
<tr>
<td>2015</td>
<td>-</td>
</tr>
<tr>
<td>TOTAL</td>
<td>$ 3,375</td>
</tr>
</tbody>
</table>

Total rent expense for the year was $4,392.

NOTE 6 – MAJOR CONTRIBUTIONS

During the year Advancement of Research for Myopathies (ARM) had contributions from eight major donors (over $5,000), representing 83% of the contribution revenues and 44% of the overall revenues.

NOTE 7 - OFF-BALANCE SHEET CREDIT RISK

Advancement of Research for Myopathies (ARM) periodically maintains balances in its various cash accounts in excess of $250,000. Such excess is not insured by the Federal Depository Insurance Corporation (FDIC).